Clinical Observation of Yishen Tonglong Decoction (益肾通癃汤) Combined with Androgen Blockade in the Treatment of Prostate Cancer with Kidney Deficiency and Toxicity Stasis Type
Author：CHEN Bangdi1, ZHU Wenxiong1,2, ZHANG Xi3, YUAN Yifeng1, CHEN Qihua1, QIN Guozheng2
Unit：1.The First Hospital of Hunan University of Chinese Medicine, Changsha Hunan 410007, China; 2.Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming Yunnan 650032, China; 3.The School of Pharmacy of Hunan University of Chinese Medicine, Changsha Hunan 410208, China
Quote：引用：陈邦第，朱文雄，张熙，袁轶峰，陈其华，秦国政.益肾通癃汤联合雄激素阻断治疗肾虚瘀毒型前列腺癌的临床观察[J].中医药导报,2025,31(7):86-90.
DOI：10.13862/j.cn43-1446/r.2025.07.014
PDF：
Download PDF
Abstract：
Objective:
To observe the clinical efficacy of Yishen Tonglong Decoction (益肾通癃汤) combined with androgen blockade in
the treatment of prostate cancer with kidney deficiency and toxicity stasis
type. Methods: A total of 108 patients with kidney deficiency and blood stasis
type prostate cancer were randomly divided into treatment group and control
group, with 54 cases in each group. The control group received androgen
blockade treatment, while the treatment group received Yishen Tonglong
Decoction in addition to the treatment in the control group. After continuous
intervention for 16 weeks, the serum levels of total prostate-specific antigen
(t-PSA), international prostate symptom score (IPSS), and traditional Chinese
medicine syndrome scores in two groups of patients before and after treatment
were observed. Results: After treatment, the serum t-PSA levels and IPSS scores
of the two groups were significantly decreased (P<0.01), and the serum t-PSA
levels and IPSS scores of the patients in the treatment group after treatment
were lower than those in the control group (P<0.01). After treatment, the
traditional Chinese medicine syndrome scores of the patients in the treatment
group were significantly decreased (P<0.01), while there was no significant
difference in the traditional Chinese medicine syndrome scores of the patients
in the control group before and after treatment (P>0.05). There was no
significant difference in the clinical efficacy between the two groups
(P>0.05). Conclusion: Yishen Tonglong Decoction combined with androgen
blockade has a good therapeutic effect in the treatment of prostate cancer with kidney deficiency and
toxicity stasis type, which can reduce the serum t-PSA level and improve the
prostate symptoms and traditional Chinese medicine syndrome manifestations of
patients.
Key words：prostate cancer; kidney deficiency and toxicity stasis; Yishen Tonglong Decoction; androgen ablation; integrated traditional Chinese and western medicine; clinical observation
摘要：
目的：观察益肾通癃汤联合雄激素阻断治疗肾虚瘀毒型前列腺癌的临床疗效。方法：纳入肾虚瘀毒型前列腺癌患者108例，按照随机数字表法随机分为治疗组和对照组，每组54例。对照组患者予雄激素阻断治疗，治疗组患者在对照组基础上加用益肾通癃汤，两组均连续干预16周。观察治疗前后两组患者血清总前列腺特异性抗原（t-PSA）水平、国际前列腺症状（IPSS）评分及中医证候评分等指标。结果：治疗后，两组患者血清t-PSA、IPSS评分均明显降低（P＜0.01），且治疗组患者治疗后血清t-PSA、IPSS评分低于对照组（P＜0.01）；治疗后，治疗组患者中医证候评分明显降低（P＜0.01），对照组患者治疗后中医证候评分与治疗前比较，差异无统计学意义（P＞0.05）；两组患者临床疗效比较，差异无统计学意义（P＞0.05）。结论：益肾通癃汤联合雄激素阻断治疗肾虚瘀毒型前列腺癌有较好疗效，能降低患者血清t-PSA水平，改善患者的前列腺症状及中医证候表现。
关键词：前列腺癌；肾虚瘀毒；益肾通癃汤；雄激素阻断；中西医结合；临床观察
Release time：2026-01-06
click-through rate：160